BidaskClub Upgrades Natus Medical (BABY) to Sell

Natus Medical (NASDAQ:BABY) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued to investors on Thursday, BidAskClub reports.

Other analysts have also recently issued research reports about the company. Zacks Investment Research raised Natus Medical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 16th. ValuEngine raised Natus Medical from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. Finally, William Blair reissued a “market perform” rating on shares of Natus Medical in a research report on Saturday, January 12th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $36.00.

Shares of Natus Medical stock opened at $26.07 on Thursday. The firm has a market capitalization of $837.11 million, a PE ratio of 18.36 and a beta of 0.52. The company has a quick ratio of 1.54, a current ratio of 2.14 and a debt-to-equity ratio of 0.17. Natus Medical has a 12 month low of $23.58 and a 12 month high of $37.95.

Natus Medical (NASDAQ:BABY) last issued its earnings results on Thursday, April 25th. The medical equipment provider reported $0.09 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.03. The business had revenue of $114.80 million during the quarter, compared to analysts’ expectations of $113.30 million. Natus Medical had a positive return on equity of 11.64% and a negative net margin of 4.32%. Natus Medical’s revenue was down 10.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.24 earnings per share. As a group, analysts predict that Natus Medical will post 1.25 earnings per share for the current fiscal year.

In related news, Director Robert A. Gunst sold 6,304 shares of Natus Medical stock in a transaction on Friday, March 1st. The stock was sold at an average price of $27.96, for a total transaction of $176,259.84. Following the completion of the sale, the director now owns 32,392 shares of the company’s stock, valued at $905,680.32. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Robert A. Gunst sold 8,304 shares of Natus Medical stock in a transaction on Monday, March 4th. The shares were sold at an average price of $28.09, for a total value of $233,259.36. Following the sale, the director now directly owns 32,392 shares of the company’s stock, valued at approximately $909,891.28. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Pearl River Capital LLC acquired a new stake in Natus Medical during the fourth quarter valued at $30,000. Meeder Asset Management Inc. acquired a new stake in Natus Medical during the first quarter valued at $38,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Natus Medical by 51.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,495 shares of the medical equipment provider’s stock valued at $85,000 after purchasing an additional 845 shares during the last quarter. Paloma Partners Management Co acquired a new stake in Natus Medical during the third quarter valued at $218,000. Finally, Janney Montgomery Scott LLC boosted its position in Natus Medical by 5.5% during the fourth quarter. Janney Montgomery Scott LLC now owns 7,097 shares of the medical equipment provider’s stock valued at $242,000 after purchasing an additional 370 shares during the last quarter. 99.26% of the stock is owned by hedge funds and other institutional investors.

Natus Medical Company Profile

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Read More: How Important is Technical Analysis of Stocks

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.